NasdaqCM - Delayed Quote USD

Moleculin Biotech, Inc. (MBRX)

7.90 -0.82 (-9.40%)

At close: October 30 at 4:00:00 PM EDT

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027

GlobeNewswire 2d ago

MBRX
-9.40%
Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial

GlobeNewswire 12d ago

MBRX
-9.40%
Moleculin Announces Reverse Stock Split

GlobeNewswire 16d ago

MBRX
-9.40%
^IXIC
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout

GlobeNewswire 1mo ago

MBRX
-9.40%
Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR

GlobeNewswire 1mo ago

MBRX
-9.40%
Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040

GlobeNewswire 1mo ago

MBRX
-9.40%
Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings

GlobeNewswire 1mo ago

MBRX
-9.40%
Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand

GlobeNewswire 1mo ago

MBRX
-9.40%
Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference

GlobeNewswire 2mo ago

MBRX
-9.40%
Moleculin Biotech (MBRX) Upgraded to Buy: Here's Why

Zacks 2mo ago

MBRX
-9.40%
Moleculin Announces Pricing of $9.3 Million Public Offering

GlobeNewswire 3mo ago

MBRX
-9.40%
Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients

GlobeNewswire 3mo ago

MBRX
-9.40%

Performance Overview

Return	MBRX	S&P 500 (^GSPC)
YTD	+138.67%	+10.73%
1-Year	-30.09%	+11.11%
3-Year	-95.36%	+81.91%

U.S. markets closed

Moleculin Biotech, Inc. (MBRX)

Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027

Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial

Moleculin Announces Reverse Stock Split

Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout

Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR

Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040

Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings

Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand

Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference

Moleculin Biotech (MBRX) Upgraded to Buy: Here's Why

Moleculin Announces Pricing of $9.3 Million Public Offering

Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients